¼¼°èÀÇ ¾çÀüÀÚ ¹æÃâ ´ÜÃþÃÔ¿µ(PET) ½ÃÀå
Positron Emission Tomography (PET)
»óǰÄÚµå : 1543847
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 194 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,464,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 25,393,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¾çÀüÀÚ ¹æÃâ ´ÜÃþÃÔ¿µ(PET) ½ÃÀåÀº 2030³â±îÁö 27¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2023³â¿¡ 20¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ¾çÀüÀÚ ¹æÃâ ´ÜÃþÃÔ¿µ(PET) ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2023-2030³â¿¡ CAGR 4.8%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 27¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ PET-CT´Â CAGR 5.0%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á±îÁö 23¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. PET-MRI ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£¿¡ CAGR 3.9%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 5¾ï 3,210¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 8.1%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¾çÀüÀÚ ¹æÃâ ´ÜÃþÃÔ¿µ(PET) ½ÃÀåÀº 2023³â¿¡ 5¾ï 3,210¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 5¾ï 9,130¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2023-2030³â CAGRÀº 8.1%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 2.5%¿Í 4.0%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.2%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¾çÀüÀÚ ¹æÃâ ´ÜÃþÃÔ¿µ(PET) ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¾çÀüÀÚ ¹æÃâ ´ÜÃþÃÔ¿µ(PET) : º¹ÀâÇÑ ÀÎü »ý¸®ÇÐÀ» ¹àÈù´Ù.

¾çÀüÀÚ ¹æÃâ ´ÜÃþÃÔ¿µ(PET)Àº ü³» ´ë»ç °úÁ¤À» ½Ã°¢È­Çϰí ÃøÁ¤ÇÒ ¼ö Àִ ÷´Ü ¿µ»ó ±â¼úÀÔ´Ï´Ù. ÇØºÎÇÐÀû ±¸Á¶¿¡ ÃÊÁ¡À» ¸ÂÃá ±âÁ¸ÀÇ À̹Ì¡ ¹æ¹ý°ú ´Þ¸® PET ½ºÄµÀº ¾çÀüÀÚ¸¦ ¹æÃâÇÏ´Â ¹æ»ç¼º ÃßÀûÀÚ¿¡¼­ °£Á¢ÀûÀ¸·Î ¹æÃâµÇ´Â °¨¸¶¼±À» °¨ÁöÇÏ¿© ±â´ÉÀû À̹Ì¡À» Á¦°øÇÕ´Ï´Ù. ÀϹÝÀûÀ¸·Î ¹æ»ç¼º ÃßÀûÀÚ´Â Ç÷ç¿À¸£µ¥¿Á½Ã±Û·çÄÚ½º(FDG)¿Í °°Àº ¹æ»ç¼ºµ¿À§¿ø¼Ò·Î Ç¥ÁöµÈ »ý¹°ÇÐÀû Ȱ¼º ºÐÀÚ·Î, ´ë»ç Ȱµ¿ÀÌ ³ôÀº Á¶Á÷¿¡ ÃàÀûµË´Ï´Ù. ¹æ»ç¼º ÃßÀûÀÚ°¡ ºØ±«ÇÏ¸é ¾çÀüÀÚ°¡ ¹æÃâµÇ¾î ÀüÀÚ¿Í Ãæµ¹ÇÏ¿© °¨¸¶¼±À» »ý¼ºÇϰí PET ½ºÄ³³Ê¿¡¼­ °¨ÁöµË´Ï´Ù. ÀÌ °úÁ¤À» ÅëÇØ ÀÓ»óÀÇ´Â »ý¹°ÇÐÀû ±â´É¿¡ ´ëÇÑ »ó¼¼ÇÑ À̹ÌÁö¸¦ »ý¼ºÇÏ¿© Áúº´ÀÇ »ý¸®Àû ¹× º´¸®ÇÐÀû °üÁ¡¿¡¼­ ±ÍÁßÇÑ ÀλçÀÌÆ®À» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀº PET À̹Ì¡À» ¾î¶»°Ô Çâ»ó½Ã۰í Àִ°¡?

±â¼úÀÇ ¹ßÀüÀº PET À̹Ì¡¿¡ Çõ¸íÀ» °¡Á®¿Í Á¤È®µµ, ÇØ»óµµ ¹× Àû¿ë ¹üÀ§¸¦ Çâ»ó½ÃÄ×À¸¸ç, PET¿Í ÄÄÇ»ÅÍ ´ÜÃþÃÔ¿µ(CT) ¹× Àڱ⠰ø¸í ¿µ»ó(MRI)°úÀÇ ÅëÇÕÀ» ÅëÇØ PET/CT ¹× PET/MRI¿Í °°Àº ÇÏÀ̺긮µå À̹Ì¡ ½Ã½ºÅÛÀÌ Åº»ýÇß½À´Ï´Ù, PETÀÇ ±â´ÉÀû ¿µ»ó ±â´É°ú CT³ª MRIÀÇ ÇØºÎÇÐÀû »ó¼¼ Á¤º¸°¡ °áÇյǾî ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ À¶ÇÕÀº Áúº´ÀÇ ±¹¼ÒÈ­ ¹× Ư¼ºÈ­¸¦ °³¼±ÇÏ´Â Á¾ÇÕÀûÀÎ Áø´Ü ÅøÀ» Á¦°øÇÕ´Ï´Ù. µðÁöÅÐ PET ½ºÄ³³ÊÀÇ °³¹ß µî °ËÃâ±â ±â¼úÀÇ ¹ßÀüÀ¸·Î À̹ÌÁöÀÇ ÇØ»óµµ¿Í ¹Î°¨µµ°¡ Å©°Ô Çâ»óµÇ¾î Áúº´À» º¸´Ù ºü¸£°í Á¤È®ÇÏ°Ô ¹ß°ßÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ ¹æ»ç¼º ÃßÀûÀÚ °³¹ßÀÇ ±â¼ú Çõ½ÅÀ¸·Î °¡½ÃÈ­ÇÒ ¼ö ÀÖ´Â ´ë»ç ¹× ºÐÀÚ °úÁ¤ÀÇ ¹üÀ§°¡ È®´ëµÇ¾î ¾Ï, ½ÉÇ÷°ü Áúȯ¿¡¼­ ½Å°æ Áúȯ¿¡ À̸£±â±îÁö ´Ù¾çÇÑ º´Å»ý¸®¸¦ PET·Î °Ë»çÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

PET À̹Ì¡ÀÇ ÁÖ¿ä ÀÀ¿ë ¹× ÀåÁ¡Àº ¹«¾ùÀΰ¡?

PET ¿µ»óÁø´ÜÀº Á¾¾çÇÐ, ½Å°æÇÐ, ¼øÈ¯±âÇÐ, °¨¿°¼º Áúȯ Áø´Ü¿¡ ³Î¸® »ç¿ëµÇ¾î ¸¹Àº ÀÓ»óÀû ÀÌÁ¡À» °¡Á®´ÙÁÝ´Ï´Ù. Á¾¾çÇп¡¼­ PET´Â ´Ù¾çÇÑ ¾ÏÀÇ ¹ß°ß, º´±â °áÁ¤, Ä¡·á È¿°ú ¸ð´ÏÅ͸µ¿¡ ÇʼöÀûÀ̸ç, Ä¡·á ¹æÄ§À» °áÁ¤ÇÏ´Â µ¥ Áß¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. ½Å°æÇп¡¼­ PET ½ºÄµÀº ³ú ´ë»çÀÇ ÀÌ»óÀ» ¹àÇô³»¾î ¾ËÃ÷ÇÏÀ̸Ӻ´, °£Áú, ÆÄŲ½¼º´°ú °°Àº ½Å°æ ÁúȯÀÇ Áø´Ü°ú ¿¬±¸¿¡ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ½ÉÀå Àü¹®ÀǵéÀº PET ¿µ»óÀ» ÅëÇØ ½É±ÙÀÇ °ü·ù¿Í »ýÁ¸ ´É·ÂÀ» Æò°¡ÇÏ¿© °ü»óµ¿¸Æ ÁúȯÀÇ Áø´Ü°ú °ü¸®¿¡ Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. ±â´ÉÀû ¿µ»óÀÌ °¡´ÉÇÑ PET´Â Áúº´ÀÇ ÁøÇàÀ» ÃßÀûÇϰí Ä¡·áÀÇ È¿°ú¸¦ Æò°¡ÇÒ ¼ö ÀÖ´Â °­·ÂÇÑ ÅøÀÔ´Ï´Ù. ¶ÇÇÑ PETÀÇ ºñħ½ÀÀû Ư¼º°ú Á¤·®Àû µ¥ÀÌÅÍ Á¦°ø ´É·ÂÀº ÀÓ»ó°ú ¿¬±¸ ¸ðµÎ¿¡¼­ ±× À¯¿ë¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù.

PET À̹Ì¡ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

¾çÀüÀÚ ¹æÃâ ´ÜÃþÃÔ¿µ(PET) ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¾Ï°ú ½Å°æ ÁúȯÀÇ À¯º´·ü Áõ°¡´Â PET À̹Ì¡ÀÌ ÀÌ·¯ÇÑ ÁúȯÀÇ Á¤È®ÇÑ Áø´Ü°ú °ü¸®¿¡ ÇʼöÀûÀ̱⠶§¹®¿¡ Áß¿äÇÑ ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖÀ¸¸ç, PET ½ºÄ³³ÊÀÇ ÇØ»óµµ, °¨µµ ¹× ¿ë·®À» Çâ»ó½ÃŰ´Â ±â¼ú ¹ßÀüµµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¾ç»ó°úÀÇ ÅëÇÕÀ¸·Î PETÀÇ ÀÓ»ó Àû¿ëÀÌ È®´ëµÇ°í Áø´Ü Á¤È®µµ°¡ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Æ¯Á¤ ´ë»ç °æ·Î¿Í ºÐÀÚ ¸¶Ä¿¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â »õ·Î¿î ¹æ»ç¼º ÃßÀûÀÚÀÇ °³¹ß·Î PET ¿µ»óÀÇ ¹üÀ§°¡ ³Ð¾îÁö°í ÀÖ½À´Ï´Ù. ºñħ½ÀÀû Áø´Ü ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ÇÔ²² ÀÓ»ó ¿¬±¸ ¹× ÀǾàǰ °³¹ß¿¡¼­ PETÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀο¡ ´õÇØ ½ÅÈï ½ÃÀåÀÇ ÀÇ·áºñ ÁöÃâ Áõ°¡¿Í ÀÇ·á ÀÎÇÁ¶ó È®´ë´Â PET ¿µ»ó ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÃÑ 42°Ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Positron Emission Tomography (PET) Market to Reach US$2.7 Billion by 2030

The global market for Positron Emission Tomography (PET) estimated at US$2.0 Billion in the year 2023, is expected to reach US$2.7 Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2023-2030. PET-CT, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$2.3 Billion by the end of the analysis period. Growth in the PET-MRI segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$532.1 Million While China is Forecast to Grow at 8.1% CAGR

The Positron Emission Tomography (PET) market in the U.S. is estimated at US$532.1 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$591.3 Million by the year 2030 trailing a CAGR of 8.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 4.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global Positron Emission Tomography (PET) Market - Key Trends and Drivers Summarized

Positron Emission Tomography (PET): Unveiling the Intricacies of Human Physiology

Positron Emission Tomography (PET) is a sophisticated imaging technique that enables the visualization and measurement of metabolic processes in the body. Unlike traditional imaging methods that focus on anatomical structures, PET scans provide functional imaging by detecting the gamma rays emitted indirectly by a positron-emitting radiotracer. Typically, the radiotracer is a biologically active molecule labeled with a radioactive isotope, such as fluorodeoxyglucose (FDG), which accumulates in tissues with high metabolic activity. When the radiotracer decays, it emits positrons that collide with electrons, producing gamma rays that are detected by the PET scanner. This process allows clinicians to generate detailed images of biological functions, offering invaluable insights into the physiology and pathology of diseases.

How Are Technological Advancements Enhancing PET Imaging?

Technological advancements have revolutionized PET imaging, enhancing its accuracy, resolution, and application scope. The integration of PET with computed tomography (CT) or magnetic resonance imaging (MRI) has resulted in hybrid imaging systems like PET/CT and PET/MRI, combining the functional imaging capabilities of PET with the anatomical detail of CT or MRI. This fusion provides a comprehensive diagnostic tool that improves disease localization and characterization. Advances in detector technology, such as the development of digital PET scanners, have significantly improved image resolution and sensitivity, allowing for earlier and more accurate disease detection. Additionally, innovations in radiotracer development have expanded the range of metabolic and molecular processes that can be visualized, enabling PET to investigate various conditions, from cancer and cardiovascular diseases to neurological disorders.

What Are the Key Applications and Benefits of PET Imaging?

PET imaging is widely used in oncology, neurology, cardiology, and infectious disease diagnosis, offering numerous clinical benefits. In oncology, PET is indispensable for detecting, staging, and monitoring the treatment response of various cancers, providing crucial information that guides therapeutic decisions. In neurology, PET scans are used to diagnose and study neurological conditions such as Alzheimer's disease, epilepsy, and Parkinson's disease, by revealing abnormalities in brain metabolism. Cardiologists use PET imaging to assess myocardial perfusion and viability, aiding in the diagnosis and management of coronary artery disease. The ability to provide functional imaging makes PET a powerful tool for tracking disease progression and evaluating the efficacy of treatments. Moreover, the non-invasive nature of PET and its ability to provide quantitative data enhance its utility in both clinical practice and research settings.

What Factors Are Driving the Growth in the PET Imaging Market?

The growth in the positron emission tomography (PET) market is driven by several factors. The increasing prevalence of cancer and neurological disorders is a significant driver, as PET imaging is crucial for the accurate diagnosis and management of these conditions. Technological advancements that enhance the resolution, sensitivity, and capabilities of PET scanners are also propelling market growth. The integration of PET with other imaging modalities, such as CT and MRI, has expanded its clinical applications and improved diagnostic accuracy. Additionally, the development of new radiotracers that target specific metabolic pathways and molecular markers is broadening the scope of PET imaging. The rising adoption of PET in clinical research and drug development, coupled with the growing demand for non-invasive diagnostic techniques, is further contributing to market growth. These factors, combined with increasing healthcare expenditure and the expansion of healthcare infrastructure in emerging markets, are driving the sustained growth of the PET imaging market.

Select Competitors (Total 42 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â